Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA regulatory pathway to commercialize treatments for rare diseases.

Aurora Therapeutics' first target is the rare inherited disease phenylketonuria, also known as PKU. Here at MIT Technology Review we’ve been writing about the gene-editing technology CRISPR since 2013 ...

The gene therapy success with Baby KJ, along with a new FDA program, have companies more interested in treating rare disease.

The biotech startup Inscripta is attempting to “democratize” CRISPR by offering it to select researchers at no cost, according to Fortune. Here are four things to know about the startup’s business ...